AI Article Synopsis
Article Abstract
Objective: To characterize the estimated risk of invasive breast cancer (IBC) in postmenopausal women without a family history of breast cancer (FHBC), baseline risk scores were calculated using the Breast Cancer Risk Assessment tool. We also analyzed the incidence rates of IBC stratified by FHBC.
Methods: For the Continuing Outcomes Relevant to Evista (CORE) study population (n = 3,991; excluding women ≥86 y of age or with a history of ductal carcinoma in situ or lobular carcinoma in situ), the prevalence of risk factors to the overall IBC risk was calculated. To evaluate IBC incidence rates, the placebo arm of the CORE trial (n = 1,275) was pooled with the placebo arm of the Raloxifene Use for the Heart trial (n = 5,047; total of 6,322 women).
Results: Common risk factors in the CORE population were age 65 years or older (78.4%) and menarche at 12 years or younger (29.4%). Incidence rates of IBC in the CORE plus Raloxifene Use for the Heart trial placebo populations correlated with IBC risk estimates; incidence rates were higher as risk scores increased. Of those who developed IBC, 65% (60/92) had scores between 1% and 2% and did not have FHBC; nearly half (43%; 40/92) had risk scores below the high-risk cutoff of 1.66%.
Conclusions: A significant portion of women who develop IBC do not have a family history of the disease. FHBC is important in assessing IBC risk; however, other relevant risk factors, together with FHBC and results from a validated tool risk assessment tool, should be jointly considered to develop a complete assessment of women's IBC risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/gme.0b013e3181fa27e7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Natural epigallocatechin-3-gallocarboxylate nanoformulation loaded doxorubicin to construct a novel and low cardiotoxicity chemotherapeutic drug for high-efficiency breast cancer therapy.
J Nanobiotechnology
December 2024
School of Life and Environmental Sciences, Shaoxing University, Shaoxing, 312000, Zhejiang, China.
Anthracycline doxorubicin (DOX) remains the first-line chemotherapeutic drug for the efficient treatment of breast cancer, but its severe cardiotoxicity limits its long-term application in clinical tumor chemotherapy. Until now, the pathogenesis mechanism of DOX-induced cardiotoxicity (DIC) is still not fully understood. According to current studies, the oxidative stress caused by the imbalance of reactive oxygen species (ROS) and reactive nitrogen species (RNS) production and mitochondrial dysfunction in myocardial cells are closely related to DIC.
View Article and Find Full Text PDFDevelopment and preliminary validation of the Dietary Self-management Behavior Questionnaire (DSMBQ) for breast cancer patients during chemotherapy: three rounds of survey.
BMC Public Health
December 2024
Department of Health Statistics, School of Public Health, The Fourth Military Medical University, Xi'an, 710032, China.
Background: Adverse effects during chemotherapy severely impact the daily diet of breast cancer (BC) patients. Engaging in dietary self-management is crucial for healthy lifestyle and recovery. This study aims to create the Dietary Self-management Behavior Questionnaire (DSMBQ) and preliminarily validate its reliability, validity, and discriminative ability for BC patients undergoing chemotherapy.
View Article and Find Full Text PDFAripiprazole-loaded niosome/chitosan-gold nanoparticles for breast cancer chemo-photo therapy.
BMC Biotechnol
December 2024
Department of Microbiology, Faculty of Veterinary and Agriculture, Islamic Azad University, Shabestar Branch, Shabestar, Iran.
Introduction: Breast cancer, a formidable global health challenge for women, necessitates innovative therapeutic strategies with enhanced efficacy and minimal side effects. Aripiprazole (ARI), a widely used schizophrenia medication, exhibits promising potential in the treatment of breast cancer. As cancer therapy evolves towards a combination approach, multimodal nano-based delivery systems, such as ARI-loaded niosomes (NIOs) combined with Chitosan-Au nanoparticles for chemo-photothermal therapy, show promise over traditional chemotherapy alone by enhancing targeted efficacy and minimizing side effects.
View Article and Find Full Text PDFUnresectable stage III NSCLC is now treated with chemoradiation (CRT) followed by immune checkpoint inhibitors (ICI). Pneumonitis, a common CRT complication, has heightened risk with ICI, potentially causing severe outcomes. Currently, there are no biomarkers to predict pneumonitis risk or differentiate between radiation-induced pneumonitis (RTP) and ICI-induced pneumonitis (IIP).
View Article and Find Full Text PDFThe Train: A Supply of Inspiration for Delivering High-Quality Cancer Care.
Ann Surg Oncol
December 2024
Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Background: The past 10 years have convincingly shown that the TRAIN-studies, with their starting point in Antoni van Leeuwenhoek (Amsterdam), have proved their significance for breast cancer patients with stage II or III human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The main aim of these studies is to maximize a positive, clinically relevant outcome with the least burdensome neoadjuvant systemic treatment option after which surgery and systemic treatment (in accordance with the current oncology guidelines) is provided.
Rationale And Conclusions: The breast cancer train studies give rise to plenty of ideas for optimization of treatment in oncology, which is in the best interest of the patient, the treating doctor or caregiver, and society.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!